TempraMed Signs Exclusive Distribution Agreement with Leading Consumer Health Distributor in Israel

Executive Summary

• TempraMed Technologies Ltd. signed a definitive exclusive commercial distribution agreement with Guri A.A.O., granting Guri rights to market and sell TempraMed’s full product line across >2,500 Israeli retail outlets (pharmacies, supermarkets, HMOs).
• The partnership is presented as the first step in TempraMed’s strategic pivot from an online B2C model to large‑scale pharmacy‑led and B2B medical payer distribution, supporting its global expansion program.
• TempraMed filed its interim financial statements for Q3 2025 (three‑ and nine‑month periods) and provided an update that the previously announced non‑brokered private placement remains active and is being advanced toward closing.

Key Details

• Distribution Agreement
• Exclusive rights granted to Guri A.A.O. for TempraMed’s “VIVI” line and upcoming temperature‑sensitive medical storage products in Israel.
• Guri reaches >2,500 outlets, including major pharmacy chains, supermarkets, HMOs, and independent pharmacies.
• Agreement aligns with TempraMed’s shift to pharmacy‑led distribution and B2B payer channels, aiming to reduce patient acquisition costs and embed temperature‑control solutions into standard care.
• Strategic Significance
• Marks the first regional partnership in a broader global expansion covering Europe, Middle East, North America, and Asia.
• TempraMed holds eight patents and regulatory approvals across major jurisdictions for cold‑chain solutions (injectables, biologics, fertility meds, GLP‑1 therapies, insulin).
• Financial Reporting
• Interim financial statements for the three‑ and nine‑month periods ended September 30 2025 have been filed on SEDAR+.
• No specific financial figures disclosed in the release.
• Private Placement Update
• The non‑brokered private placement announced on October 21 2025 is still being pursued; closing subject to customary conditions and regulatory approvals.
• Proceeds are intended to fund strategic initiatives, including the new distribution partnership and the broader shift to pharmacy‑led channels.
• Executive Comments
• Ron Nagar (CEO, TempraMed) highlighted the partnership as a “major step” toward making temperature‑safe medication storage a global standard.
• Oded Guri (Owner & CEO, Guri A.A.O.) expressed confidence that the collaboration will drive growth for both parties.

Notable Quotes

• Ron Nagar, CEO, TempraMed: “Partnering with a top‑tier distributor like Guri aligns perfectly with our pivot from a digital B2C model to pharmacy‑led distribution and B2B payor channels… This is a major step in making temperature‑safe medication storage the global standard.”
• Oded Guri, Owner & CEO, Guri A.A.O.: “Retail executives have already expressed a strong willingness to start selling the products. I’m proud to be among the first distributors of TempraMed products in the global market…”